A new study published in the BMJ reveals that glucagon-like peptide 1 (GLP-1) medications—originally designed for type 2 diabetes and weight loss—are associated with a significant reduction in the risk of all types of substance use disorders. This includes alcohol, nicotine, cannabis, opioids, and cocaine addiction. The findings suggest these drugs may not only prevent new addictions but also reduce life-threatening events like overdoses and suicide attempts.
Unexpected Benefits Across Multiple Disorders
Researchers analyzed data from over 600,000 U.S. veterans with type 2 diabetes over three years. Those taking GLP-1 medications showed a 14% overall reduction in substance use disorder risk, with a particularly striking 25% decrease in opioid use. The benefits were seen within the first year and persisted for the duration of the study.
This widespread effect is unusual; as clinical epidemiologist Ziyad Al-Aly notes, “This is an obesity and diabetes drug; this is not an addiction drug. So the big surprise was: it was consistently working across all substances.”
Dramatic Improvements in Existing Addictions
The study also examined veterans already struggling with addiction. Results were compelling: GLP-1 treatment was linked to a 31% reduction in emergency department visits, a 26% decline in hospital admissions, a 39% decrease in overdoses, and a 25% reduction in suicidal ideation. Perhaps most significantly, drug-related deaths were cut by 50%.
Neuroscientists emphasize that these findings are not entirely surprising given what is known about brain pathways. Alex DiFeliceantonio of Virginia Tech points to the “powerful” impact on drug-related deaths as a particularly promising aspect for future treatments.
The Science Behind the Effect
The exact mechanism remains unclear, but researchers theorize GLP-1 medications may dampen addictive cravings by influencing reward pathways in the brain. Al-Aly likens it to “quieting ‘drug noise’,” the relentless mental chatter driving compulsive behavior—similar to how these drugs already reduce obsessive thoughts about food.
GLP-1 mimics a gut hormone that boosts insulin and satiety, but its receptors are also found in brain circuits controlling reward, motivation, and impulse control. Slowing digestion may also play a role in reducing alcohol consumption, as suggested by recent research.
Future Directions
While the study focused primarily on older white male veterans, similar trends were observed in a subset of women. Further research is needed to determine optimal dosages and which GLP-1 drugs are most effective for addiction treatment. Clinical trials, like the one led by Patricia Grigson at Pennsylvania State University, are already underway to test Ozempic as an opioid use disorder treatment.
“Some [GLP-1] medicines are going to work better for some people than others,” Grigson notes. “We have a lot to learn still about the appropriate regimen.”
The findings raise the possibility of a “common biologic pathway” underlying all addictions, potentially leading to new druggable targets. The next step is understanding exactly how GLP-1 works—and how to harness its effects safely and effectively.
